Cidara Therapeutics stock price target raised to $150 at H.C. Wainwright
PositiveFinancial Markets

Cidara Therapeutics has received a significant boost as H.C. Wainwright has raised its stock price target to $150. This adjustment reflects growing confidence in the company's potential and could attract more investors, highlighting the positive outlook for Cidara's future developments.
— Curated by the World Pulse Now AI Editorial System